Magnetic Field Induced Quantum Criticality via new Asymptotically AdS_5 Solutions

Using analytical methods, we derive and extend previously obtained numerical results on the low temperature properties of holographic duals to four-dimensional gauge theories at finite density in a nonzero magnetic field. We find a new asymptotically AdS_5 solution representing the system at zero temperature. This solution has vanishing entropy density, and the charge density in the bulk is carried entirely by fluxes. The dimensionless magnetic field to charge density ratio for these solutions is bounded from below, with a quantum critical point appearing at the lower bound. Using matched asymptotic expansions, we extract the low temperature thermodynamics of the system. Above the critical magnetic field, the low temperature entropy density takes a simple form, linear in the temperature, and with a specific heat coefficient diverging at the critical point. At the critical magnetic field, we derive the scaling law s ~ T^{1/3} inferred previously from numerical analysis. We also compute the full scaling function describing the region near the critical point, and identify the dynamical critical exponent: z=3. These solutions are expected to holographically represent boundary theories in which strongly interacting fermions are filling up a Fermi sea. They are fully top-down constructions in which both the bulk and boundary theories have well known embeddings in string theory.Comment: 50 page

The Baryonic Phase in Holographic Descriptions of the QCD Phase Diagram

We study holographic models of the QCD temperature-chemical potential phase diagram based on the D3/D7 system with chiral symmetry breaking. The baryonic phase may be included through linked D5-D7 systems. In a previous analysis of a model with a running gauge coupling a baryonic phase was shown to exist to arbitrarily large chemical potential. Here we explore this phase in a more generic phenomenological setting with a step function dilaton profile. The change in dilaton generates a linear confining $\bar{q}q$ potential and opposes the screening effect of temperature. We show that the persistence of the baryonic phase depends on the step size and that QCD-like phase diagrams can be described. The baryonic phase's existence is qualitatively linked to the existence of confinement in Wilson loop computations in the background.Comment: 21 pages, 7 figure

Towards a Holographic Model of the QCD Phase Diagram

We describe the temperature-chemical potential phase diagrams of holographic models of a range of strongly coupled gauge theories that display chiral symmetry breaking/restoration transitions. The models are based on the D3/probe-D7 system but with a phenomenologically chosen running coupling/dilaton profile. We realize chiral phase transitions with either temperature or density that are first or second order by changing the dilaton profile. Although the models are only caricatures of QCD they show that holographic models can capture many aspects of the QCD phase diagram and hint at the dependence on the running coupling.Comment: 11 pages, 9 figures, v2: minor corrections, Invited contribution to an AdS/CFT edition of Journal of Physics

The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis

Background. Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The addition of the immunomodulator mifamurtide to adjuvant cytotoxic chemotherapy was associated with a significant improvement in 6-year overall survival (OS) in young patients with resectable osteosarcoma, leading to its approval in Europe and other countries. Very limited real-world data are reported on its use. Methods. We retrospectively evaluated data from osteosarcoma patients who received mifamurtide in the adjuvant setting. Data were obtained from medical records in 2 high-volume bone sarcoma centers. The aim of this study was to collect real-world data on mifamurtide safety and efficacy in Greece. Results. We identified 15 patients with completely resected osteosarcoma who received mifamurtide from September 2015 to January 2020. Median age at diagnosis was 24 years old (16–76). Osteosarcoma arose in the lower extremities (n = 12), in the upper extremities (n = 2) or in the ilium (n = 1). The majority of patients (n = 13) received cisplatin/doxorubicin/methotrexate as perioperative chemotherapy and the remaining patients cisplatin/doxorubicin. After a median follow-up of 46.9 months (range, 32.8–61.1), the median recurrence-free survival was 58.7 months (range, 18.5–98.8) and the median OS 64.1 months (range, 25.6–102.6). Except for fever and chills, the only adverse event probably related to mifamurtide was pericarditis (n = 1). Conclusions. Mifamurtide was well tolerated in a Greek osteosarcoma population, including patients older than 30 years. The small sample size and the non-comparative design do not allow drawing conclusions on the drug benefit in terms of survival. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature